<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04215926</url>
  </required_header>
  <id_info>
    <org_study_id>20191126V2</org_study_id>
    <nct_id>NCT04215926</nct_id>
  </id_info>
  <brief_title>NAFLD in HIV-infected Patients</brief_title>
  <acronym>NAFLDIH</acronym>
  <official_title>The Epidemiological Investigation and Pathogenesis of NAFLD in HIV-infected Patients: a Cross-sectional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Public Health Clinical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Public Health Clinical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of NAFLD (nonalcoholic fatty liver disease) in HIV-infected patients is higher
      than that in general population, but the causes of morbidity and pathogenesis have not been
      fully explored. The investigators are planning to consecutively enroll 400 cases HIV-positive
      outpatients, and to detect NAFLD by ultrasound. The fecal and blood samples were also
      collected to explore the mechanism of NAFLD. The investigators aimed to determine the
      prevalence and risk factors of NAFLD in HIV infected patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>morbidity of nonalcoholic fatty liver disease</measure>
    <time_frame>1 month</time_frame>
    <description>NAFLD was diagnosed using ultrasound</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>HIV-infection/Aids</condition>
  <condition>NAFLD</condition>
  <arm_group>
    <arm_group_label>HIV-monoinfected outpatients</arm_group_label>
    <description>No intervention; cross-sectional study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention; cross-sectional study</intervention_name>
    <description>No intervention; cross-sectional study</description>
    <arm_group_label>HIV-monoinfected outpatients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and fecal sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected outpatients who was not coinfected with other form of viral hepatitis or drug
        induced liver disease, some severe systematic disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18~70 y;

          -  HIV-positive patients;

          -  written the informed consent

        Exclusion Criteria:

          -  coinfected with HBV, HCV;

          -  secondary causes of fatty liver (eg, consumption of amiodarone and tamoxifen) and
             decompensated liver disease;

          -  significant alcohol consumption (&gt;20 g per day for man, &gt;10 g per day for woman);

          -  received antibiotics in preceding two months;

          -  autoimmune disease;

          -  severe heart, lung, kidney, brain, blood diseases or other important systemic
             diseases;

          -  pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hongzhou Lu, Ph.D</last_name>
    <phone>+86-021-37990333</phone>
    <phone_ext>3222</phone_ext>
    <email>luhongzhou@fudan.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hongzhou Lu, PI</last_name>
    <phone>+86-021-37990333</phone>
    <phone_ext>3222</phone_ext>
    <email>luhongzhou@fudan.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201508</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 29, 2019</study_first_submitted>
  <study_first_submitted_qc>December 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Public Health Clinical Center</investigator_affiliation>
    <investigator_full_name>Hongzhou Lu</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>HIV infection</keyword>
  <keyword>NAFLD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

